Rhinomed Ltd (ASX:RNO) has been building its international presence and connections amongst the international investment and pharmaceutical community this year. In March, Michael Johnson was the keynote 'Rising Star' presentation at the Master Investor Show in London.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today reported its 2015 financial results and business update. During the year, the company made significant progress on the development of its portfolio of cellbased therapies for the treatment of osteoarthritis and other musculoskeletal disorders, oncology and dermatology diseases for the human and animal health markets.
iQ3Corp Ltd (ASX:IQ3) are pleased to present the operational and financial review for iQ3Corp Limited for the financial year ending 30th June 2015.
Australian respiratory technology company Rhinomed Ltd (ASX:RNO) is pleased to advise it has increased its production line capacity at the ChinaMed production facility.
Leading Australia-based medical device company, Compumedics Limited (ASX:CMP), is pleased to announce revenue and earnings growth for the year ending 30 June 2015. Comparable shipped and invoiced sales were $33.5m compared to $30.8m in the previous year.
Australian respiratory technology company Rhinomed Ltd (ASX:RNO), is pleased to announce its Mute snoring and sleep technology will be available on pharmacy shelves in the United Kingdom from late October 2015.
iQ3Corp Ltd (ASX:IQ3) today announced that through its fully owned subsidiary in the U.S., iQ Capital LLC, it is applying to obtain the necessary licenses to operate an investment banking business dedicated to life sciences.
